.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fuji
Baxter
Covington
Dow
UBS
Farmers Insurance
Johnson and Johnson
US Department of Justice
Cerilliant
Deloitte

Generated: July 27, 2017

DrugPatentWatch Database Preview

FANAPT Drug Profile

« Back to Dashboard

Which patents cover Fanapt, and what generic Fanapt alternatives are available?

Fanapt is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and seventy-four patent family members in thirty-one countries.

The generic ingredient in FANAPT is iloperidone. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the iloperidone profile page.

Summary for Tradename: FANAPT

Patents:10
Applicants:1
NDAs:1
Suppliers / Packagers: see list3
Bulk Api Vendors: see list78
Clinical Trials: see list6
Patent Applications: see list1,039
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FANAPT at DailyMed

Pharmacology for Tradename: FANAPT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009ABRXYesNo► Subscribe► SubscribeYY ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009ABRXYesNo► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FANAPT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-007May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-005May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-004May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-006May 6, 2009► Subscribe► Subscribe
Vanda Pharms Inc
FANAPT
iloperidone
TABLET;ORAL022192-003May 6, 2009► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FANAPT

Drugname Dosage Strength RLD Submissiondate
iloperidoneTablets1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, & 12 mgFanapt5/6/2013

Non-Orange Book Patents for Tradename: FANAPT

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,591,745 (4-heteroaryl)-1-[(2,3-dihydro-1H-isoindol-2-yl)alkyl] piperidines and related compounds and their therapeutic utility► Subscribe
5,658,911 Heteroarylpiperidines, and their use as antipsychotics and analgetics► Subscribe
6,043,240 3-heteroaryl-1-pyrrolidinealkylamines and derivatives thereof and their therapeutic utility► Subscribe
RE37478 1-(arylthioalkyl, arylaminoalkyl, or arylmethylenealkyl)-4-(heteroaryl)piperazines and related compounds useful as antipsychotics and analgesics► Subscribe
5,593,995 2-[(4-heteroaryl-1-piperazinyl)alkyl]-1,3-indandiones and related compounds and their therapeutic utility► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: FANAPT

Country Document Number Estimated Expiration
JapanH07501055► Subscribe
Germany69233796► Subscribe
Portugal963984► Subscribe
World Intellectual Property Organization (WIPO)9309102► Subscribe
Hong Kong1006710► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Queensland Health
Healthtrust
Cipla
McKinsey
Dow
Daiichi Sankyo
Chubb
Federal Trade Commission
Covington
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot